OPN1SW and hepatocellular carcinoma: To date, National Comprehensive Cancer Network (NCCN) guidelines have only recommended sorafenib (GIDEON) and nivolumab (CheckMate-040) for advanced HCC with CP B-graded liver function [3, 4, 7].